On April 20, 2020 GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, reported unaudited consolidated financial results for the three months ended 31 March 2020 (Press release, GC Pharma, APR 29, 2020, View Source [SID1234556791]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(1) Results from continuing operations (Green Cross MS’ blood bag business has been classified as discontinued operations)

(2) Results and percentages compare to equivalent 2019 period

Financial Highlights

Delivered total revenue growth of 8.6% KRW 307.8 billion (2019 Q1: 283.3 billion), and operation profit increased 238.9% to KRW 6.1 billion (2019 Q1: 1.6 billion) in the first quarter.
Unconsolidated revenues increased 8.1%, reflecting strong international sales.
Double-digit growth in consolidated subsidiaries, including Green Cross MS and Green Cross LabCell.
Green Cross local sales up 5.5% reflecting strong CHC segment performance.
Green Cross international sales benefited from strong vaccines growth, Flu Vx and VZ Vx sales up 711%, 1,095% respectively.
Operating profit growth driven by favourable mix and bottom line reflected anticipated headwinds.